Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chau, Katherine
BA3011-002, NCT04681131: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC	Active, not recruiting	2	240	Europe, US, RoW	CAB-AXL-ADC, BA3011, PD-1 inhibitor	BioAtla, Inc.	Non-Small-Cell Lung Cancer	08/25	08/25
Zinoli, Linda
BA3011-002, NCT04681131: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC	Active, not recruiting	2	240	Europe, US, RoW	CAB-AXL-ADC, BA3011, PD-1 inhibitor	BioAtla, Inc.	Non-Small-Cell Lung Cancer	08/25	08/25
BA3021-001, NCT03504488: CAB-ROR2-ADC Safety and Efficacy Study in Patients with TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)	Active, not recruiting	1/2	420	Europe, US, RoW	CAB-ROR2-ADC, BA3021, PD-1 inhibitor	BioAtla, Inc.	Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer	12/24	12/24